Widefield Fundus Fluorescein Angiography Features of Uveitis Associated with Juvenile Idiopathic Arthritis

ABSTRACT

Purpose

To evaluate the wide-field fundus fluorescein angiography (WFA) characteristics of uveitis associated with juvenile idiopathic arthritis (JIA-uveitis).

Methods

Retrospective review of records. WFA with Spectralis (Heidelberg) of JIA-uveitis patients were analyzed using the scoring system by Angiography Scoring for Uveitis Nomenclature.

Results

Thirty-seven eyes of 20 patients were studied. A total score of at least 1 was noted in 27 eyes (72.97%). WFA features included optic disc hyperfluorescence (51.35%), macular leakage (27.03%), retinal vascular staining/leakage at posterior pole (27.03%) and peripheral retina (64.86%), capillary leakage at the posterior pole (37.84%), and peripheral retina (59.46%). A decision to change the management plan was made in 8 of 9 patients with bilateral quiet anterior chambers after WFA results.

Conclusion

More than 70% of JIA-uveitis eyes showed some WFA-evidence of posterior segment inflammation, which changed the course of therapy for a major proportion of patients with no clinically active anterior chamber inflammation.

KEYWORDS:

• Perivascular leak
• ocular inflammation
• capillary leak
• optic disc hyperfluorescence
• panuveitis

Acknowledgments

We sincerely acknowledge the help of Andrew Stephenson and Ambika Manhapra.

Disclosure statement

Dr. C Stephen Foster declares the following:

Consultancies with Aldeyra Therapeutics (Lexington, MA), Allakos (Redwood City, CA), Bausch & Lomb Surgical, Inc (Rancho Cucamonga, CA), Eyegate Pharma (Waltham, MA), Genentech (South San Francisco, CA), Novartis (Cambridge, MA), pSivida (Watertown, MA)

Grants or grants pending with Aciont (Salt Lake City, UT), Alcon (Aliso Viejo, CA), Aldeyra Therapeutics (Lexington, MA), Bausch & Lomb (Rochester, NY), Clearside Biomedical (Alpharetta, GA), Dompé pharmaceutical (Milan, Italy), Eyegate Pharma (Waltham, MA), Mallinckrodt pharmaceuticals (Staines-upon-Thames, UK), Novartis Pharmaceuticals (Cambridge, MA), pSivida (Watertown, MA), Santen (Osaka, Japan).

Payment for lectures including service on speaking bureaus: Alcon (Aliso Viejo, CA), Allergan (Dublin, Ireland), Mallinckrodt pharmaceuticals (Staines-upon-Thames, UK).

Stock or Stock Options: Eyegate Pharma (Waltham, MA)

Dr. Stephen D. Anesi declares the following:

Consultancies with Santen (Osaka, Japan), Mallinckrodt (Staines-upon-Thames, UK), Allakos (Redwood City, CA), Eyepoint (Watertown, MA), and Takeda (Tokyo, Japan).

Speakerships with AbbVie (Chicago, IL), Mallinckrodt (Staines-upon-Thames, UK), and Eyepoint (Watertown, MA).

Dr. Peter Chang declares the following:

Consultancies with Eyepoint (Watertown, MA) and Alimera (Alpharetta, GA).

Speakerships with AbbVie (Chicago, IL), Mallinckrodt (Staines-upon-Thames, UK), and Eyepoint (Watertown, MA).

All other authors have no proprietary or commercial interest in any materials discussed in this article or additional financial disclosures to declare.

Data availability statement

The data that support the findings of this study are available from the corresponding author under reasonable request.

SUPPLEMENTARY MATERIAL

Supplemental data for this article can be accessed on the publisher’s website